Hologic Boston Consulting Group Matrix
Visual. Strategic. Downloadable.
Curious where Hologic’s product lines really sit—Stars, Cash Cows, Dogs, or Question Marks? This snapshot teases the picture; buy the full BCG Matrix to get quadrant-by-quadrant placement, data-backed recommendations, and strategic moves you can act on. You’ll get a ready-to-present Word report plus an Excel summary so you can rework numbers and make decisions fast. Purchase now and skip the legwork—get clarity and a roadmap to smarter allocation today.
Stars
Panther molecular diagnostics platform
Panther sits in Stars: high market share and a rapidly expanding test menu keep utilization and pull-through rising as each new assay leverages the same installed base. Every added assay increases throughput and lab stickiness, offsetting heavy upfront cash burn from placements, service and field support. The flywheel economics justify continued investment to widen the menu and lock in clinical labs.
Genius 3D mammography (tomosynthesis)
Genius 3D mammography leads as global screening shifts from 2D to tomosynthesis—US DBT adoption reached about 80% by 2024, and Hologic holds roughly 60% share of the tomosynthesis screening market, driving high volumes and replacements. Clinical superiority and brand recognition convert to durable revenue as adoption matures. Sales require capital for systems (~$400–600k), training and service, but supported deployments win share and recurring cash.
Aptima HPV & women’s STI assays
Aptima HPV and women’s STI assays sit in the Stars quadrant as screening mandates and rising testing intensity drive strong market growth, with global HPV testing market forecasts around $3–4 billion by mid-decade (2024 estimates). Panther workflow and peer-reviewed clinical data continue to reinforce share, shortening adoption cycles. High reagent pull-through makes promotion and access investments pay back quickly through recurring consumable revenue. Continue to invest in market access and guideline wins to sustain momentum.
Breast biopsy systems (Affirm, Brevera, Eviva)
Procedure growth tracks DBT/tomo screening—DBT adoption reached about 75% in the US by 2023, driving an ~8% YoY rise in image-guided biopsy volumes (2023–24); Affirm, Brevera, Eviva capture downstream work and generate recurring high-value disposable revenue above the capital sale; success requires ongoing KOL engagement, training, and placement support while targeting centers upgrading to 3D workflows.
- Category: Stars
- Drivers: DBT adoption ~75% (2023), biopsy volumes +8% YoY
- Model: capital + high-margin disposables, KOL/training-dependent
NovaSure & MyoSure surgical suite
NovaSure and MyoSure form a Stars position as minimally invasive gynecologic procedures shift outpatient; ASC share of benign gynecologic procedures reached an estimated 55% in 2024, driving demand. Strong physician preference and installed technique know‑how sustain momentum, with NovaSure showing low‑double‑digit procedure growth and MyoSure mid‑teens growth in 2024. Continued account wins require education, access, and territory coverage; invest to expand indications and ASC penetration to capture a ~$600M+ US addressable market.
- Physician preference: high — retention of installed base
- 2024 growth: NovaSure low‑double digits; MyoSure mid‑teens
- Priority investments: education, territory coverage, ASC partnerships
High stickiness platform, DBT ~60% lead, $3–4B HPV consumables, ASC-driven device growth
Stars: Panther platform drives high reagent pull‑through and stickiness; Genius 3D leads with ~60% tomosynthesis share as US DBT adoption ~80% (2024); Aptima HPV benefits from a $3–4B global market (mid‑decade) and strong consumable margins; NovaSure/MyoSure growing low‑double to mid‑teens (2024) as ASC shift accelerates.
| Product | 2024 metric | Growth | Key driver |
|---|---|---|---|
| Panther | High pull‑through | — | Installed base, assays |
| Genius 3D | ~60% tomosynthesis share | High | DBT adoption ~80% |
| Aptima | HPV market $3–4B | Strong | Recurring reagents |
| NovaSure/MyoSure | ASC share ~55% | Low‑double to mid‑teens | Outpatient shift |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix for Hologic: strategic guidance on which product lines to invest, hold, or divest with quadrant-level risks.
Customizable Excel Spreadsheet
One-page overview placing each Hologic business unit in a quadrant
Cash Cows
ThinPrep Pap test & cytology franchise
ThinPrep Pap test & cytology franchise holds a commanding share in a mature, guideline-driven cervical screening market; 2024 growth remained low (low single-digit) but volumes stayed steady. Predictable, high-margin consumables with modest sales expense produce significant free cash flow. Reliability and scale throw off cash—maintain quality and ops efficiency: milk, don’t overfeed.
Installed-base service and consumables (breast imaging)
Installed-base breast imaging is a cash cow: a large fleet on service contracts delivers steady parts and detector-swap revenue with low growth but high renewal and excellent gross margins. Minimal promotion is needed—focus is uptime, SLAs, and predictable consumable spend. Operational levers are route optimization, faster parts turns, and value-based pricing to extract incremental cash.
Mature CT/GC testing in developed markets
Mature CT/GC testing in developed markets shows stable volumes (roughly flat year‑over‑year, ±1%) with entrenched lab workflows and high share—a classic maintenance play for Hologic. Reagent pull‑through is dependable and margin‑rich (gross margins often in the high‑60s), while US STI burden remains large (~1.7M chlamydia, ~700k gonorrhea cases in 2024 provisional CDC data). Protect contracts and tighten supply chains to defend recurring revenue and reagent attach rates.
Specimen imaging (Faxitron, Trident HD) replacement cycle
Replacement-driven demand for Faxitron and Trident HD is steady, backed by strong brand trust and entrenched lab workflows; competition is present but slow-moving, helping margins remain intact. Sales intensity is modest after footprint saturation; uptime guarantees and trade-in programs are pivotal to keep replacement cycles active. Hologic reported approximately $4.0B revenue in FY2024.
- Replacement-led demand
- Slow-moving competition → margins hold
- Modest post-install sales intensity
- Prioritize uptime and trade-ins
Breast biopsy disposables recurring stream
Breast biopsy disposables form a procedure-linked, recurring revenue stream for Hologic tied to installed platforms, contributing to Hologic’s FY2024 revenue of about 4.0 billion and delivering predictable volume flows from routine diagnostic workflows.
Market growth is low overall, but favorable pricing and consumable mix sustain strong margins and reduce the need for heavy promotion once accounts convert; retention is driven by procedure dependence and installed base economics.
- Procedure-linked recurring sales
- Forecastable volume from installed base
- Low market growth, margin support from pricing/mix
- Minimal promotion after account win
- Standardize kits/logistics to widen contribution
High-margin consumables & services fuel steady cash; FY2024 ≈ $4.0B
ThinPrep/cytology: dominant, low-single-digit 2024 growth, steady volumes and high-margin consumables driving free cash flow. Installed-base breast imaging: large service fleet, high renewal, low growth, strong parts/contract margins. CT/GC reagents: stable volumes, high‑60s gross margins; CDC provisional 2024: ~1.7M chlamydia, ~700k gonorrhea; Hologic FY2024 revenue ≈ $4.0B.
| Product | Role | 2024 datapoints | Margin |
|---|---|---|---|
| ThinPrep | Consumables cash flow | Low‑single‑digit growth, steady volumes | High |
| Breast imaging service | Service/parts recurring | Large installed base, low growth | High |
| CT/GC reagents | Reagent pull‑through | CDC: ~1.7M chlamydia, ~700k gonorrhea | High‑60s% |
| Company | Total | FY2024 revenue ≈ $4.0B | — |
Full Transparency, Always
Hologic BCG Matrix
The file you're previewing here is the exact Hologic BCG Matrix report you'll receive after purchase. No watermarks, no demo placeholders—just the fully formatted, analysis-ready document. Once bought it lands in your inbox as an editable, print-ready file you can present or adapt immediately. No surprises, no extra steps—just plug it into your planning and go.
Visual. Strategic. Downloadable.
Curious where Hologic’s product lines really sit—Stars, Cash Cows, Dogs, or Question Marks? This snapshot teases the picture; buy the full BCG Matrix to get quadrant-by-quadrant placement, data-backed recommendations, and strategic moves you can act on. You’ll get a ready-to-present Word report plus an Excel summary so you can rework numbers and make decisions fast. Purchase now and skip the legwork—get clarity and a roadmap to smarter allocation today.
Stars
Panther molecular diagnostics platform
Panther sits in Stars: high market share and a rapidly expanding test menu keep utilization and pull-through rising as each new assay leverages the same installed base. Every added assay increases throughput and lab stickiness, offsetting heavy upfront cash burn from placements, service and field support. The flywheel economics justify continued investment to widen the menu and lock in clinical labs.
Genius 3D mammography (tomosynthesis)
Genius 3D mammography leads as global screening shifts from 2D to tomosynthesis—US DBT adoption reached about 80% by 2024, and Hologic holds roughly 60% share of the tomosynthesis screening market, driving high volumes and replacements. Clinical superiority and brand recognition convert to durable revenue as adoption matures. Sales require capital for systems (~$400–600k), training and service, but supported deployments win share and recurring cash.
Aptima HPV & women’s STI assays
Aptima HPV and women’s STI assays sit in the Stars quadrant as screening mandates and rising testing intensity drive strong market growth, with global HPV testing market forecasts around $3–4 billion by mid-decade (2024 estimates). Panther workflow and peer-reviewed clinical data continue to reinforce share, shortening adoption cycles. High reagent pull-through makes promotion and access investments pay back quickly through recurring consumable revenue. Continue to invest in market access and guideline wins to sustain momentum.
Breast biopsy systems (Affirm, Brevera, Eviva)
Procedure growth tracks DBT/tomo screening—DBT adoption reached about 75% in the US by 2023, driving an ~8% YoY rise in image-guided biopsy volumes (2023–24); Affirm, Brevera, Eviva capture downstream work and generate recurring high-value disposable revenue above the capital sale; success requires ongoing KOL engagement, training, and placement support while targeting centers upgrading to 3D workflows.
- Category: Stars
- Drivers: DBT adoption ~75% (2023), biopsy volumes +8% YoY
- Model: capital + high-margin disposables, KOL/training-dependent
NovaSure & MyoSure surgical suite
NovaSure and MyoSure form a Stars position as minimally invasive gynecologic procedures shift outpatient; ASC share of benign gynecologic procedures reached an estimated 55% in 2024, driving demand. Strong physician preference and installed technique know‑how sustain momentum, with NovaSure showing low‑double‑digit procedure growth and MyoSure mid‑teens growth in 2024. Continued account wins require education, access, and territory coverage; invest to expand indications and ASC penetration to capture a ~$600M+ US addressable market.
- Physician preference: high — retention of installed base
- 2024 growth: NovaSure low‑double digits; MyoSure mid‑teens
- Priority investments: education, territory coverage, ASC partnerships
High stickiness platform, DBT ~60% lead, $3–4B HPV consumables, ASC-driven device growth
Stars: Panther platform drives high reagent pull‑through and stickiness; Genius 3D leads with ~60% tomosynthesis share as US DBT adoption ~80% (2024); Aptima HPV benefits from a $3–4B global market (mid‑decade) and strong consumable margins; NovaSure/MyoSure growing low‑double to mid‑teens (2024) as ASC shift accelerates.
| Product | 2024 metric | Growth | Key driver |
|---|---|---|---|
| Panther | High pull‑through | — | Installed base, assays |
| Genius 3D | ~60% tomosynthesis share | High | DBT adoption ~80% |
| Aptima | HPV market $3–4B | Strong | Recurring reagents |
| NovaSure/MyoSure | ASC share ~55% | Low‑double to mid‑teens | Outpatient shift |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix for Hologic: strategic guidance on which product lines to invest, hold, or divest with quadrant-level risks.
Customizable Excel Spreadsheet
One-page overview placing each Hologic business unit in a quadrant
Cash Cows
ThinPrep Pap test & cytology franchise
ThinPrep Pap test & cytology franchise holds a commanding share in a mature, guideline-driven cervical screening market; 2024 growth remained low (low single-digit) but volumes stayed steady. Predictable, high-margin consumables with modest sales expense produce significant free cash flow. Reliability and scale throw off cash—maintain quality and ops efficiency: milk, don’t overfeed.
Installed-base service and consumables (breast imaging)
Installed-base breast imaging is a cash cow: a large fleet on service contracts delivers steady parts and detector-swap revenue with low growth but high renewal and excellent gross margins. Minimal promotion is needed—focus is uptime, SLAs, and predictable consumable spend. Operational levers are route optimization, faster parts turns, and value-based pricing to extract incremental cash.
Mature CT/GC testing in developed markets
Mature CT/GC testing in developed markets shows stable volumes (roughly flat year‑over‑year, ±1%) with entrenched lab workflows and high share—a classic maintenance play for Hologic. Reagent pull‑through is dependable and margin‑rich (gross margins often in the high‑60s), while US STI burden remains large (~1.7M chlamydia, ~700k gonorrhea cases in 2024 provisional CDC data). Protect contracts and tighten supply chains to defend recurring revenue and reagent attach rates.
Specimen imaging (Faxitron, Trident HD) replacement cycle
Replacement-driven demand for Faxitron and Trident HD is steady, backed by strong brand trust and entrenched lab workflows; competition is present but slow-moving, helping margins remain intact. Sales intensity is modest after footprint saturation; uptime guarantees and trade-in programs are pivotal to keep replacement cycles active. Hologic reported approximately $4.0B revenue in FY2024.
- Replacement-led demand
- Slow-moving competition → margins hold
- Modest post-install sales intensity
- Prioritize uptime and trade-ins
Breast biopsy disposables recurring stream
Breast biopsy disposables form a procedure-linked, recurring revenue stream for Hologic tied to installed platforms, contributing to Hologic’s FY2024 revenue of about 4.0 billion and delivering predictable volume flows from routine diagnostic workflows.
Market growth is low overall, but favorable pricing and consumable mix sustain strong margins and reduce the need for heavy promotion once accounts convert; retention is driven by procedure dependence and installed base economics.
- Procedure-linked recurring sales
- Forecastable volume from installed base
- Low market growth, margin support from pricing/mix
- Minimal promotion after account win
- Standardize kits/logistics to widen contribution
High-margin consumables & services fuel steady cash; FY2024 ≈ $4.0B
ThinPrep/cytology: dominant, low-single-digit 2024 growth, steady volumes and high-margin consumables driving free cash flow. Installed-base breast imaging: large service fleet, high renewal, low growth, strong parts/contract margins. CT/GC reagents: stable volumes, high‑60s gross margins; CDC provisional 2024: ~1.7M chlamydia, ~700k gonorrhea; Hologic FY2024 revenue ≈ $4.0B.
| Product | Role | 2024 datapoints | Margin |
|---|---|---|---|
| ThinPrep | Consumables cash flow | Low‑single‑digit growth, steady volumes | High |
| Breast imaging service | Service/parts recurring | Large installed base, low growth | High |
| CT/GC reagents | Reagent pull‑through | CDC: ~1.7M chlamydia, ~700k gonorrhea | High‑60s% |
| Company | Total | FY2024 revenue ≈ $4.0B | — |
Full Transparency, Always
Hologic BCG Matrix
The file you're previewing here is the exact Hologic BCG Matrix report you'll receive after purchase. No watermarks, no demo placeholders—just the fully formatted, analysis-ready document. Once bought it lands in your inbox as an editable, print-ready file you can present or adapt immediately. No surprises, no extra steps—just plug it into your planning and go.
Original: $10.00
-65%$10.00
$3.50Description
Visual. Strategic. Downloadable.
Curious where Hologic’s product lines really sit—Stars, Cash Cows, Dogs, or Question Marks? This snapshot teases the picture; buy the full BCG Matrix to get quadrant-by-quadrant placement, data-backed recommendations, and strategic moves you can act on. You’ll get a ready-to-present Word report plus an Excel summary so you can rework numbers and make decisions fast. Purchase now and skip the legwork—get clarity and a roadmap to smarter allocation today.
Stars
Panther molecular diagnostics platform
Panther sits in Stars: high market share and a rapidly expanding test menu keep utilization and pull-through rising as each new assay leverages the same installed base. Every added assay increases throughput and lab stickiness, offsetting heavy upfront cash burn from placements, service and field support. The flywheel economics justify continued investment to widen the menu and lock in clinical labs.
Genius 3D mammography (tomosynthesis)
Genius 3D mammography leads as global screening shifts from 2D to tomosynthesis—US DBT adoption reached about 80% by 2024, and Hologic holds roughly 60% share of the tomosynthesis screening market, driving high volumes and replacements. Clinical superiority and brand recognition convert to durable revenue as adoption matures. Sales require capital for systems (~$400–600k), training and service, but supported deployments win share and recurring cash.
Aptima HPV & women’s STI assays
Aptima HPV and women’s STI assays sit in the Stars quadrant as screening mandates and rising testing intensity drive strong market growth, with global HPV testing market forecasts around $3–4 billion by mid-decade (2024 estimates). Panther workflow and peer-reviewed clinical data continue to reinforce share, shortening adoption cycles. High reagent pull-through makes promotion and access investments pay back quickly through recurring consumable revenue. Continue to invest in market access and guideline wins to sustain momentum.
Breast biopsy systems (Affirm, Brevera, Eviva)
Procedure growth tracks DBT/tomo screening—DBT adoption reached about 75% in the US by 2023, driving an ~8% YoY rise in image-guided biopsy volumes (2023–24); Affirm, Brevera, Eviva capture downstream work and generate recurring high-value disposable revenue above the capital sale; success requires ongoing KOL engagement, training, and placement support while targeting centers upgrading to 3D workflows.
- Category: Stars
- Drivers: DBT adoption ~75% (2023), biopsy volumes +8% YoY
- Model: capital + high-margin disposables, KOL/training-dependent
NovaSure & MyoSure surgical suite
NovaSure and MyoSure form a Stars position as minimally invasive gynecologic procedures shift outpatient; ASC share of benign gynecologic procedures reached an estimated 55% in 2024, driving demand. Strong physician preference and installed technique know‑how sustain momentum, with NovaSure showing low‑double‑digit procedure growth and MyoSure mid‑teens growth in 2024. Continued account wins require education, access, and territory coverage; invest to expand indications and ASC penetration to capture a ~$600M+ US addressable market.
- Physician preference: high — retention of installed base
- 2024 growth: NovaSure low‑double digits; MyoSure mid‑teens
- Priority investments: education, territory coverage, ASC partnerships
High stickiness platform, DBT ~60% lead, $3–4B HPV consumables, ASC-driven device growth
Stars: Panther platform drives high reagent pull‑through and stickiness; Genius 3D leads with ~60% tomosynthesis share as US DBT adoption ~80% (2024); Aptima HPV benefits from a $3–4B global market (mid‑decade) and strong consumable margins; NovaSure/MyoSure growing low‑double to mid‑teens (2024) as ASC shift accelerates.
| Product | 2024 metric | Growth | Key driver |
|---|---|---|---|
| Panther | High pull‑through | — | Installed base, assays |
| Genius 3D | ~60% tomosynthesis share | High | DBT adoption ~80% |
| Aptima | HPV market $3–4B | Strong | Recurring reagents |
| NovaSure/MyoSure | ASC share ~55% | Low‑double to mid‑teens | Outpatient shift |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix for Hologic: strategic guidance on which product lines to invest, hold, or divest with quadrant-level risks.
Customizable Excel Spreadsheet
One-page overview placing each Hologic business unit in a quadrant
Cash Cows
ThinPrep Pap test & cytology franchise
ThinPrep Pap test & cytology franchise holds a commanding share in a mature, guideline-driven cervical screening market; 2024 growth remained low (low single-digit) but volumes stayed steady. Predictable, high-margin consumables with modest sales expense produce significant free cash flow. Reliability and scale throw off cash—maintain quality and ops efficiency: milk, don’t overfeed.
Installed-base service and consumables (breast imaging)
Installed-base breast imaging is a cash cow: a large fleet on service contracts delivers steady parts and detector-swap revenue with low growth but high renewal and excellent gross margins. Minimal promotion is needed—focus is uptime, SLAs, and predictable consumable spend. Operational levers are route optimization, faster parts turns, and value-based pricing to extract incremental cash.
Mature CT/GC testing in developed markets
Mature CT/GC testing in developed markets shows stable volumes (roughly flat year‑over‑year, ±1%) with entrenched lab workflows and high share—a classic maintenance play for Hologic. Reagent pull‑through is dependable and margin‑rich (gross margins often in the high‑60s), while US STI burden remains large (~1.7M chlamydia, ~700k gonorrhea cases in 2024 provisional CDC data). Protect contracts and tighten supply chains to defend recurring revenue and reagent attach rates.
Specimen imaging (Faxitron, Trident HD) replacement cycle
Replacement-driven demand for Faxitron and Trident HD is steady, backed by strong brand trust and entrenched lab workflows; competition is present but slow-moving, helping margins remain intact. Sales intensity is modest after footprint saturation; uptime guarantees and trade-in programs are pivotal to keep replacement cycles active. Hologic reported approximately $4.0B revenue in FY2024.
- Replacement-led demand
- Slow-moving competition → margins hold
- Modest post-install sales intensity
- Prioritize uptime and trade-ins
Breast biopsy disposables recurring stream
Breast biopsy disposables form a procedure-linked, recurring revenue stream for Hologic tied to installed platforms, contributing to Hologic’s FY2024 revenue of about 4.0 billion and delivering predictable volume flows from routine diagnostic workflows.
Market growth is low overall, but favorable pricing and consumable mix sustain strong margins and reduce the need for heavy promotion once accounts convert; retention is driven by procedure dependence and installed base economics.
- Procedure-linked recurring sales
- Forecastable volume from installed base
- Low market growth, margin support from pricing/mix
- Minimal promotion after account win
- Standardize kits/logistics to widen contribution
High-margin consumables & services fuel steady cash; FY2024 ≈ $4.0B
ThinPrep/cytology: dominant, low-single-digit 2024 growth, steady volumes and high-margin consumables driving free cash flow. Installed-base breast imaging: large service fleet, high renewal, low growth, strong parts/contract margins. CT/GC reagents: stable volumes, high‑60s gross margins; CDC provisional 2024: ~1.7M chlamydia, ~700k gonorrhea; Hologic FY2024 revenue ≈ $4.0B.
| Product | Role | 2024 datapoints | Margin |
|---|---|---|---|
| ThinPrep | Consumables cash flow | Low‑single‑digit growth, steady volumes | High |
| Breast imaging service | Service/parts recurring | Large installed base, low growth | High |
| CT/GC reagents | Reagent pull‑through | CDC: ~1.7M chlamydia, ~700k gonorrhea | High‑60s% |
| Company | Total | FY2024 revenue ≈ $4.0B | — |
Full Transparency, Always
Hologic BCG Matrix
The file you're previewing here is the exact Hologic BCG Matrix report you'll receive after purchase. No watermarks, no demo placeholders—just the fully formatted, analysis-ready document. Once bought it lands in your inbox as an editable, print-ready file you can present or adapt immediately. No surprises, no extra steps—just plug it into your planning and go.
